Cardiomyopathy Cell Models for Research

Cardiomyopathy encompasses a group of diseases affecting the heart muscle, leading to impaired cardiac function and often heart failure. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, with cardiomyopathies contributing significantly to morbidity and mortality. The prevalence of hypertrophic cardiomyopathy (HCM) is estimated at 1 in 500 in the general population, while dilated cardiomyopathy (DCM) affects approximately 1 in 2500. The 5-year survival rate for heart failure, a common consequence of cardiomyopathy, is around 50% (NCI). Key risk factors include genetic mutations, viral infections, and metabolic disorders. The clinical impact is substantial, with many patients requiring transplantation or device therapy.

Cardiomyopathy is ideal for mechanistic studies due to its well-defined genetic basis and the availability of patient-derived induced pluripotent stem cells (iPSCs). Subtypes such as HCM, DCM, and arrhythmogenic right ventricular cardiomyopathy (ARVC) offer distinct molecular pathways. Public datasets, including the ClinVar database, provide extensive genetic variant information. Open questions remain regarding genotype-phenotype correlations and the role of modifier genes. Gene-edited cell models enable precise dissection of pathogenic mechanisms and are essential for developing targeted therapies.

Cardiomyopathy arises from mutations in genes encoding sarcomeric proteins, cytoskeletal components, and ion channels. The major pathways include:

• • Sarcomere dysfunction: Mutations in MYH7, MYBPC3, TNNT2, and TNNI3 disrupt actin-myosin cross-bridge cycling, leading to impaired contractility.
• • Calcium handling abnormalities: Mutations in RYR2, CASQ2, and PLN affect calcium release and reuptake, causing arrhythmias and contractile dysfunction.
• • Desmosomal disruption: Mutations in PKP2, DSP, and DSG2 impair cell-cell adhesion, particularly in ARVC.
• • Mitochondrial dysfunction: Mutations in mitochondrial DNA or nuclear genes (e.g., TAZ) lead to energy deficiency and oxidative stress.

Data from ClinVar and COSMIC.

Key signaling networks involved in cardiomyopathy include:

• • MAPK/ERK pathway: Hyperactivation due to sarcomeric mutations leads to hypertrophy.
• • PI3K/AKT pathway: Impaired signaling contributes to apoptosis and fibrosis.
• • TGF-β signaling: Promotes fibrosis and remodeling.
• • Wnt/β-catenin pathway: Involved in cardiac development and regeneration.
• • Calcineurin/NFAT pathway: Mediates hypertrophic gene expression.

Common cell lines used in cardiomyopathy research include:

Organoids (cardiac microtissues) offer 3D architecture and multicellular composition, better recapitulating in vivo conditions.

Animal models for cardiomyopathy include:

• • Genetically engineered mouse models (GEMMs): Knock-in of specific mutations (e.g., MYH7 R403Q) recapitulates HCM.
• • Induced models: Administration of drugs (e.g., doxorubicin) or pressure overload (TAC) induces DCM.
• • Patient-derived xenografts (PDX): Used for cancer, but not typical for cardiomyopathy; however, humanized mouse models with human iPSC-derived cardiomyocytes are emerging.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations. For example:

• • ACTC1 knockout in AC16 cells to study actin dysfunction.
• • MYH7 knock-in (e.g., R403Q) in iPSC-CMs to model HCM.
• • TNNT2 knockout to investigate troponin T function.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent, reproducible systems. These models are essential for functional validation and drug screening.

Knockout and knock-in cell lines allow functional validation of disease-associated genes. For instance, knocking out MYBPC3 in iPSC-CMs recapitulates the haploinsufficiency phenotype, enabling study of disease mechanisms. Knock-in of pathogenic variants helps establish causality.

Isogenic pairs (wild-type vs. mutant) are used for high-throughput screening to identify compounds that rescue the phenotype. For example, screening for drugs that normalize calcium handling in RYR2 mutant cells. Resistance modeling is less relevant, but for DCM, screening for compounds that prevent fibrosis is possible.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, selectively kill mutant cells. This approach can uncover novel therapeutic targets and biomarkers. For cardiomyopathy, such screens could identify modifiers that exacerbate or alleviate the disease phenotype.